Claims
- 1. An oxyethylene-containing compound, comprising at least one oxyethylene moiety coupled to a crosslinking moiety through a covalent bond, wherein the oxyethylene moiety has a discrete length, and wherein the covalent bond is selected from the group consisting of an amine bond, an ester bond, and an amide bond.
- 2. The compound of claim 1, wherein the oxyethylene moiety comprises a radical selected from the group consisting of
- 3. The compound of claim 1, wherein the oxyethylene moiety comprises a 4,7,10-trioxa-1,13-tridecane diamine radical.
- 4. The compound of claim 1, wherein the oxyethylene moiety comprises a 3,6,9-trioxaundecanedioic acid radical.
- 5. The compound of claim 1, wherein the oxyethylene moiety comprises a radical selected from the group consisting of
- 6. The oxyethylene-containing compound
- 7. The compound of claim 1, wherein the crosslinking moiety is selected from the group consisting of bifunctional and trifunctional crosslinking moieties.
- 8. The compound of claim 1, wherein the crosslinking moiety comprises an alkyl moiety having a displaceable leaving group.
- 9. The compound of claim 1, wherein the crosslinking moiety comprises a carboxylic acid group.
- 10. The compound of claim 1, wherein the crosslinking moiety is a selected from the group consisting of
- 11. A compound, comprising a first component coupled to an oxyethylene linker through a first covalent bond, wherein the oxyethylene linker comprises at least one oxyethylene moiety coupled to a crosslinking moiety through a second covalent bond, wherein the oxyethylene moiety has a discrete length.
- 12. The compound of claim 11, wherein the first component has low solubility in an aqueous environment.
- 13. The compound of claim 11, wherein the first component is a biologically active molecule.
- 14. The compound of claim 11, wherein the first component is a therapeutic agent.
- 15. The compound of claim 14, wherein the therapeutic agent is selected from the group consisting of a ubiquinone and derivatives thereof.
- 16. The compound of claim 15, wherein the ubiquinone is ubiquinone 50.
- 17. The compound of claim 14, wherein the therapeutic agent is selected from the group consisting of vitamin B12 and derivatives thereof.
- 18. The compound of claim 11, wherein the first covalent bond is cleavable in vivo.
- 19. A pharmaceutical composition, comprising the compound of claims 14, 15, or 17 and a pharmaceutically acceptable carrier.
- 20. A method for preparing an oxyethylene-linked compound, comprising:
reacting a crosslinking agent with an oxyethylene-containing compound to form an oxyethylene linker having a first covalent bond between the crosslinking agent and the oxyethylene compound, wherein the oxyethylene compound comprises an oxyethylene moiety having a discrete length; and reacting the oxyethylene-linker with a first component to form a second covalent bond between the oxyethylene-linker and the first component.
- 21. A method for preparing an oxyethylene-containing compound, comprising:
reacting a first crosslinking agent with a first oxyethylene-containing compound to form a second oxyethylene-containing compound having a first covalent bond between the crosslinking agent and the oxyethylene compound, wherein the oxyethylene compound comprises an oxyethylene moiety having a discrete length; and reacting the second oxyethylene-containing compound with a second crosslinking agent to form a second covalent bond between the crosslinking agent and the oxyethylene compound to form an oxyethylene-containing compound.
- 22. The method of claim 21, further comprising reacting the oxyethylene-containing compound with a first component to form a covalent bond between the second oxyethylene-containing compound and the first component.
- 23. The method of claim 21, wherein the first and second crosslinking agents are the same.
- 24. The method of claims 20 or 21, wherein the oxyethylene moiety comprises a radical selected from the group consisting of
- 25. The methods of claims 20 or 21, wherein the oxyethylene moiety comprises a 4,7,10-trioxa-1,13-tridecane diamine radical.
- 26. The methods of claims 20 or 21, wherein the oxyethylene moiety comprises a 3,6,9-trioxaundecanedioic acid radical.
- 27. The methods of claims 20 or 21, wherein the oxyethylene moiety comprises a radical selected from the group consisting of
- 28. The methods of claims 20 or 21, wherein the crosslinking agent is selected from the group consisting of
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation of application Ser. No. 09/062,286, filed Apr. 17, 1998, which is a continuation of international application Serial No. PCT/US96/16760, filed Oct. 18, 1996, which claims the benefit of provisional application Serial No. 60/005,599, filed Oct. 19, 1995.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60005599 |
Oct 1995 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09062286 |
Apr 1998 |
US |
Child |
09962840 |
Sep 2001 |
US |
Parent |
PCT/US96/16760 |
Oct 1996 |
US |
Child |
09062286 |
Apr 1998 |
US |